Probiotics in Combination with C16 Peptide and Angiopoietin-1 Synergistically Ameliorate Multiple Sclerosis in Mice Authors: Qiang Li, Yi Zhao, Lu Bai, Lu-Ping Tang, Shu Han Published: 2026 ABSTRACT AbstractBackgroundMultiple sclerosis (MS) is a debilitating autoimmune disease of the central nervous system (CNS), characterized by demyelination, axonal loss, and neuronal injury. At present, effective treatment options remain limited. Prior research demonstrated the protective effects of a compound that consists of C16 peptide and angiopoietin-1 (C16-Ang-1) in experimental autoimmune encephalomyelitis (EAE), a validated animal model of MS. This study aims to investigate the potential synergistic effects of probiotics with C16+Ang-1, and elucidate its underlying mechanisms in mice.MethodsC57/BL6 mice were randomly assigned to control, vehicle, probiotics, and C16+Ang-1+probiotics groups. Histological examinations, behavioral tests, and 16S rRNA gene sequencing of fecal samples, were conducted to determine the levels of CNS inflammation, demyelination and axonal loss, neuronal survival, and functional recovery.ResultsCompared to the probiotics group, the C16+Ang-1+probiotics group exhibited significant synergistic effects. Specifically, the combined treatment with C16+Ang-1+probiotics had significantly greater effects than probiotics alone in reducing inflammatory severity in the CNS and colon, improving the microenvironment, protecting the gut-blood barrier, and preserving blood-brain barrier integrity. These effects collectively led to the greater amelioration of functional disability in the mouse model of MS. Further mechanistic studies suggested that these effects involved the modulation of the brain-gut axis, and maintenance of gut microbiota homeostasis.ConclusionThese findings demonstrate that the combination of probiotics and C16-Ang-1 acts synergistically to ameliorate MS in mice, resulting in a greater effect. Therefore, this combination therapy warrants further investigation to explore its potential clinical benefits, ultimately improving the care for patients with MS.Keywords: multiple sclerosis, gut-brain axis, experimental autoimmune encephalomyelitis, probiotic, angiopoietin-1, C16 peptide, inflammation Introduction Multiple sclerosis (MS) is a debilitating chronic autoimmune disease of the central nervous system (CNS) that affects the brain and spinal cord, with clinical manifestations, such as limb weakness and paralysis.1 MS is driven by autoreactive immune cells that infiltrate the CNS, which target myelin antigens, and trigger leukocyte-mediated inflammation, leading to demyelination, axonal injury or loss, and neuronal damage or death.2 At present, the exact causes and pathogenic mechanisms remain unclear. Furthermore, there is presently no cure for MS, and the effective treatment options are limited, making the search for new therapeutics a priority in this field. Recent research has established a link between gut microbiota and the CNS via the gut-brain axis, showing bidirectional communication through endocrine, neural, and immune pathways. The changes in gut microbial composition can modulate inflammatory responses in MS.3 Gut dysbiosis, which often results from gastrointestinal disorders, may elevate the levels of lipopolysaccharides (LPS), pro-inflammatory cytokines, monocytes, and T helper cells, disrupting the blood-brain barrier (BBB) and intestinal barrier, and increasing permeability. This “leaky” gut and pro-inflammatory intestinal environment may alter communication with the CNS and, in turn, contribute to CNS inflammation and disease pathogenesis.4 Furthermore, the disruption of the intestinal barrier and BBB can result in the accumulation of misfolded proteins, neuronal demyelination, and axonal damage, contributing to the pathogenesis of neurodegenerative disorders, including MS. Recent research in animal models of MS has suggested that the gut microbiota influences the immune system and pathophysiology of experimental autoimmune encephalomyelitis (EAE)/MS.5 Probiotic intake has been demonstrated to restore the integrity of the intestinal barrier and BBB, potentially ameliorating these neurodegenerative disorders, including MS.1 For instance, Lactobacillus species, which is known for their roles in food fermentation, health promotion, and therapeutic benefits, can protect against gastric mucosal inflammation, and restore the balance of the gastric microbiota.6 Furthermore, lactobacilli exert protective effects against oxidative stress and neurotoxicity, improving brain function and memory performance,7 and safeguarding injured neurons in MS.8 In order to further investigate its effects on immune and inflammatory responses, the investigators planned to administer the probiotic Lactobacilli plantarum oral solution to modulate the gut-brain axis in EAE (a well-validated and most widely used animal model of MS research) induced by oligodendrocyte glycoprotein peptide 35–55 (MOG peptide), which mimics the progressive pathological process of primary progressive MS.9,10 Previous research suggests that the infiltration of extensive leukocytes into the CNS plays a critical role in driving the pathogenesis and progression of MS and EAE. Given that integrin αυβ3 mediates leukocyte adhesion and migration, the αυβ3-binding peptide is capable of blocking αυβ3, thereby reducing monocyte transmigration across the endothelial cell layer.11 The synthetic C16 peptide (KAFDITYVRLKF), which represents a functional laminin domain, selectively binds to αυβ3 integrin, and interferes with a leukocyte ligand necessary for transmigration, thereby attenuating monocyte transmigration across the endothelial cell layer.12 Furthermore, immune cells that successfully traverse the BBB can disrupt the CNS microenvironment. As such, regulating the passage of immune cells across the BBB is crucial for maintaining homeostasis in a healthy brain, and alleviating MS-associated pathological changes.13 Angiopoietin-1 (Ang-1), an agonist ligand for the Tie-2 receptor, is critical for establishing and maintaining vascular maturation, integrity, and stabilization. The Ang-1/Tie-2/non-receptor protein tyrosine phosphatase pathway has been demonstrated to prevent BBB breakdown, and reduce vascular permeability under inflammatory conditions.14 Existing therapeutic models for EAE/MS typically act through distinct, singular modes. These models target the peripheral immune system, prevent pathological leukocyte infiltration at the BBB, or modulate the gut microbiome to restore intestinal barrier integrity.15–17 However, each model has inherent limitations. For instance, probiotics can effectively restore gut barrier function, but cannot directly prevent already-activated immune cells from crossing a disrupted BBB. Conversely, BBB-targeted therapies can block leukocyte trafficking, but do not address the upstream source of systemic inflammation originating from gut dysbiosis.18 To date, no model has simultaneously integrated the blockade of pathological leukocyte infiltration at the BBB with the proactive restoration of gut microbial homeostasis. Building on previous findings that the patented drug of the investigators (a compound of C16 peptide and Ang-1) reduces BBB permeability14 and suppresses inflammatory cell infiltration,19 and intrigued by recent insights into the gut-brain axis and beneficial role of probiotics, the present study was conducted with the aim of investigating the potential synergistic effects of probiotics with C16+Ang-1, and exploring its potential mechanisms in a mouse model of MS. The findings from the present study may inform the development of new therapeutic approaches for MS. Materials and Methods Ethics Approval The present study was approved by the Animal Ethics Committee of Zhejiang University (Hangzhou, Zhejiang, China; Approval no.: ZJU20250372). All procedures involving experimental animals were performed in full compliance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals, as well as the ARRIVE guidelines. Equipment Constant temperature cryo-slicer (Shandon Cryotome, AS620E, USA); low-speed/high-speed centrifuge (Centrifuge 5417R, Eppendorf); Bio-Rad MRC-1024UV laser confocal imaging system; fluorescence microscope (Axiophot 2, Zeiss); spectrophotometer (Biophotometer); Leca Quin microscopic image analysis system; microplate reader (WellScan MKII); upright fluorescence microscope (Olympus BX61); transmission electron microscope (Thermo Fisher Scientific Talos L120C TEM). Investigational Treatments The C16 peptide and Ang-1 were sourced from Shanghai Science Peptide Biological Technology (Shanghai, China). C16 peptide was dissolved in distilled water that contained 0.3% acetic acid, filter-sterilized (0.22 μm), and neutralized to pH 7.4 with NaOH to a final concentration of 2 mg/mL. Ang-1 was solubilized in distilled water to a final concentration of 800 μg/mL. The lyophilized probiotic mixture, which consisted of eight strains (Lactobacillus lactis LP45, Bacillus casei L551, Bifidobacterium bifidum TMC3115, Lactobacillus paracasei L578, Bacillus acidophilus LA28, Lactobacillus murinus HN001, Lactobacillus BAL531 and HN019, and Streptococcus thermophilus L551), was purchased from Osteoform (Maxorb Health Products, Austin, TX, USA). A fresh solution was prepared daily by suspending the probiotics in sterile water to achieve a dose of 1.109 CFU/day/mouse. The vehicle control (sterile water alone) was prepared fresh daily under the same conditions. Establishment of the EAE Mouse Model, Grouping, and Treatments A total of 100 female C57/BL6 mice (eight weeks old) were obtained from the Zhejiang University Laboratory Animal Services Centre (Hangzhou, Zhejiang, China). These mice were randomly assigned to four groups (n=25 per group): control, vehicle, probiotics, and C16+Ang-1+probiotics groups. The mouse EAE model was induced using the MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) (Shanghai Science Peptide Biological Technology Co., Ltd., Shanghai, China) and pertussis toxin (PTX), as previously reported.9 Briefly, each mouse in the vehicle, probiotics, and C16+Ang-1+probiotics groups was subcutaneously immunized with 200 μg of MOG35-55 peptide emulsified in complete Freund’s adjuvant (CFA), which contains 500 μg of heat-killed Mycobacterium tuberculosis. PTX was intraperitoneally administered at 300 ng/100 μL in phosphate-buffered saline (PBS) at 24 hours post-immunization (pi). Mice in the control group received an equal volume of CFA emulsion mixed with 0.9% saline to maintain consistency. Daily observations for signs of disability were conducted, with the clinical severity graded on a 0–5 scale:9 0, no abnormalities; 1, mild loss of tail tonicity; 2, complete tail flaccidity; 3, onset of ataxia and/or partial hindlimb paresis; 4, total paralysis of hindlimbs; 5, moribund state or death. Then, the disability scores were meticulously documented daily throughout the 8-week study period by researchers who were blinded to the group assignments. Mice in the probiotics group were given the probiotic mixture (1×109 CFU/day at 10 mL/kg of body weight) via oral gavage once daily from day 1 to 14. Mice in the C16+Ang-1+probiotics group received an intravenous mixture of 0.5 mL of C16 and 0.5 mL of Ang-1, which delivered 400 μg of Ang-1 and 1 mg of C16 peptide, and an oral probiotic mixture once daily for two weeks. The control and vehicle groups were orally administered with 1 mL of sterile water, and intravenously administered with 1 mL of PBS for two weeks, respectively. All experimental mice were housed in controlled chambers with regulated humidity and temperature. For those with clinical scores of 4 or 5, manual bladder emptying was conducted three or more times per day. Collection of Tissue Samples Mice were sacrificed at three weeks (peak stage) or five weeks (recovery stage) after EAE induction. Then, mice were anesthetized with sodium pentobarbital, and underwent intracardiac perfusion initially with pre-chilled saline to remove blood, followed by 4% paraformaldehyde (pH 7.4) for tissue preservation. Afterwards, the brain and spinal cord were carefully dissected. Half of each was fixed in 4% paraformaldehyde for four hours, and subsequently transferred to a 30% sucrose solution for 48 hours for cryoprotection prior to immunohistochemistry. The coronal tissue sections (10 µm thick) were prepared using a freezing microtome and cryostat (Leica, Nussloch, Germany), and processed. The other half was fixed in 5% glutaraldehyde for the subsequent transmission electron microscopy (TEM).9 Next, the colon was collected, and the mesentery was removed. Then, the intestinal segment was ligated at both ends, and fixed in Carnoy’s fixative for up to 12 hours. After fixation, the tissues were dehydrated and embedded in paraffin.20 Alcian Blue-Periodic Acid Schiff (AB-PAS) Staining The colon sections were deparaffinized and hydrated, stained with Alcian blue solution for 10–15 minutes, counterstained with Nuclear Fast Red solution for 5–10 minutes, and rinsed with running water. For PAS staining, the tissue sections were washed with water for two minutes, incubated with periodic acid for five minutes, stained with Schiff for 10–20 minutes, and counterstained with hematoxylin. Finally, the sections were sealed with neutral gum, and the goblet cell mucin secretion was observed under an optical microscope (C13210–01, HAMAMATSU, Japan).21 Immunohistochemistry The tissue sections were incubated at 4°C for 24 hours with primary antibodies that targeted CD4, CD68, nuclear factor kappa B (NF-κB), caspase 3, myelin basic protein (MBP), neurofilament H (NF-H), glutamate, CHAT, GABA, 5-HT, cyclooxygenase-2 (COX-2), Tie-2, ZO-1, CD206, CD86, CD19, vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), GFAP, IL-17A, and NK1.1. Following three PBS washes, the sections were incubated at 37°C for one hour with the secondary goat anti-rabbit IgG or goat anti-mouse IgG. Detailed information on the primary and secondary antibodies utilized for the immunohistochemistry is provided in Supplementary. Table S1. Next, the tissue samples were mounted with Fluoromount-G® anti-fade mounting medium to preserve fluorescence. Then, the immunoreactive areas were identified and randomly chosen for analysis. For each mouse, five tissue sections (n=5 per mouse) were examined, with three distinct fields per section chosen for evaluation. All measurements were conducted by a blinded investigator using the ImageJ software (NIH, Bethesda, MD, USA) to ensure unbiased assessment. Eriochrome Cyanine R and Bielschowsky Silver Staining A modified Eriochrome Cyanine R staining method was used to assess the extent and severity of white matter demyelination. The tissue slices (n=5 per group) were dried at 37°C for one to two hours, treated with xylene for one hour, and rehydrated through a graded series of ethanol. After rinsing in tap water, followed by deionized water, the sections were differentiated in 5% ferric ammonium sulfate for 5–10 minutes. Following another rinse in deionized water, the sections were dehydrated, cleared with xylene, and coverslipped. Subsequently, the severity of demyelination was evaluated on an established scale of 0 to 5:13 0, normal; 1, rare foci; 2, small, scattered areas; 3, confluent perivascular or subpial lesions; 4, massive demyelination affecting half the spinal cord, accompanied by CNS parenchymal infiltrates; and 5, extensive demyelination throughout the entire spinal cord, with CNS parenchymal infiltrates. Axonal damage and loss were evaluated using the Bielschowsky Silver Stain Kit (Abcam), according to manufacturer’s protocol. Axonal loss was graded, as follows:13 grade 0, none; grade 1, less than 25% loss in the superficial layer; grade 2, more than 25% loss in deeper layers; grade 3, widespread diffuse loss. Transmission Electron Microscopy (TEM) Samples of the lumbar spinal cord and cerebral cortex (n=5 per group) were fixed in 2.5% glutaraldehyde, and post-fixed in 1% osmium tetroxide. After three washes in 0.1 M of phosphate buffer, the tissues were dehydrated in a graded ethanol series (30–95%) for five minutes each, followed by three washes in absolute ethanol for 10 minutes each. Then, the samples were incubated in 1,2-propylene oxide (PO), and infiltrated with a PO:Epon mixture (1:1). Following the overnight incubation in pure Epon, the samples were embedded in fresh Epon, and polymerized at 60°C for 72 hours.13 Ultrathin (90 nm) sections were cut from the embedded samples, and placed on 200-mesh copper grids. Then, the grids were stained with filtered 8% uranyl acetate and 3% lead citrate for 20 minutes, followed by three washes with distilled water.13 Electron micrographs were acquired from both the lumbar spinal cord and cerebral cortex. The G-ratio was determined for each sample group using the ImageJ software. TdT-Mediated dUTP Nick-End Labeling (TUNEL) Assay The brain and spinal cord tissues (n=5 per group) were fixed overnight in 4% paraformaldehyde, rinsed with PBS, dehydrated using alcohol, isopropanol and n-butanol, and finally embedded in paraffin. Following the protocol of the TUNEL kit (DAKO, Carpinteria, CA, USA), the tissue sections were subjected to antigen retrieval by immersion in sodium citrate buffer (0.1 M, pH 6.2). Subsequently, the slides were incubated with DNase-free proteinase K (100 μL) for 30 minutes. Afterwards, the TACS nuclease reaction mix (Roche) was applied, which consisted of 50 μL of reaction mix and 500 μL of diluent per slide, followed by 30-minute incubation. Next, a labeling solution was prepared from 50 μL of the fluorescein-labeled solution and 450 μL of the enzyme solution. Then, 50 μL of this mixture was applied to each slide, and incubated for 60 minutes. After dehydration through a graded ethanol series and xylene, the sample sections were mounted with neutral gum, and examined under a fluorescence light microscope (BX61, Olympus; Nikon TE-300). TUNEL-positive cells were quantified using the ImageJ software. Nissl Staining Nissl staining was conducted to evaluate the neuronal morphology and survival in the brain and spinal cord. Tissue sections (n=5 per group) were incubated with 100 μL of 1% cresyl violet dye (Sigma-Aldrich, St. Louis, MO, USA) at 37°C for two hours, followed by three 10-minute washes with PBS. After dehydration through a graded ethanol series and xylene, the sections were mounted using resin, and examined under a light microscope (Nikon TE-300) at ×400 magnification. Healthy neurons were identified by its large, multipolar, pyramidal morphology, distinct nuclei, and prominent Nissl substance (rough endoplasmic reticulum). Fluorogold Retrograde Tracing In order to assess the extent of spared descending axons that reached the lumbar enlargement, retrograde tracing was performed using Fluorogold (FG, n=5 per group). At two weeks, pi, 2% FG solution was administered into the lumbar enlargement via a glass pipette inserted into the spinal cord at coordinates 0.3 mm lateral to the midline and 0.5 mm deep from the dorsal surface. After one week, mice were sacrificed for histological analysis. Then, the transverse sections (20 µm thick) were collected from the sensorimotor cortex and cervical spinal cord enlargement. Afterwards, FG-labeled neurons with visible nuclei were bilaterally counted to prevent the duplication of individual cells. Enzyme-Linked Immunosorbent Assay (ELISA) ELISA was performed to quantify the serum cytokine levels. Blood samples (n=5 per group) were collected at two weeks after the completion of treatment, immediately treated with heparin, and centrifuged at 1,000 × g for 20 minutes, followed by 10,000 × g for 10 minutes to isolate the serum. Then, the serum was added to a 96-well plate pre-coated with specific antibodies against interleukin (IL)-1β (dilution 1:400), IL-6 (dilution 1:400), IL-10 (dilution 1:400), IL-2 (dilution 1:200), and tumor necrosis factor-α (TNF-α, dilution 1:200) (all from R and D System). After the one-hour incubation at 37°C, a secondary antibody (dilution 1:2,000) was added, and the plates were incubated for another one hour at 37°C. Then, the absorbance at 450 nm was measured using the Bio-Rad Model 680 microplate reader to determine the cytokine concentrations. Evans Blue (EB) Staining Vascular integrity and BBB permeability were evaluated by EB staining (n=5 per group). Briefly, mice were anesthetized and intravenously injected with 2% EB solution at a dosage of 4 mL/kg via the femoral vein. After 2-hour circulation, mice were perfused with saline (300 mL) to clear the vasculature of any residual dye. Next, the tissue sections were examined under ultraviolet light. Then, the extravasated EB, which indicated increased vascular permeability and BBB disruption, was visualized as red fluorescence, and the staining intensity was quantified using the ImageJ software. For the further quantitative analysis, the EB dye was extracted from homogenized tissue samples by incubation in N, N-dimethylformamide (Sigma-Aldrich) for 72 hours at room temperature in the dark. Then, the homogenate was centrifuged (10,000 × g, 25 minutes). Afterwards, the supernatant was collected to measure the optical density (OD) at 620 nm using a spectrophotometer (OptiMax, Molecular Devices) to quantify the EB concentration. Assessment of Intestinal Permeability Intestinal permeability was evaluated by measuring the flux of fluorescein isothiocyanate (FITC)-Dextran 4000 (4 kDa, CAS:60842–46-8, MedChemExpress). Mice were fasted for four hours, and administered with FITC-dextran 4000 (600 mg/kg) via oral gavage. After four hours, blood samples (n=5 per group) were collected, and the plasma was isolated by centrifugation. Then, the fluorescence intensity of FITC-dextran 4000 in plasma was measured using a multimode plate reader (Varioskan Flash, Thermo Fisher Scientific), with excitation at 488 nm and emission at 525 nm. A standard curve generated by serially diluting FITC-dextran in PBS was used to determine the FITC-dextran concentration. 16S rRNA Gene Sequencing At the peak of the EAE, fecal samples (n=5 per group) were taken from mice, flash-frozen in liquid nitrogen, and stored at −80°C, with three replicates per group. Then, the genomic DNA was extracted using the PowerSoil® DNA Isolation Kit (Qiagen). The entire 16S rRNA gene was amplified using primers (27F: AGRGTTTGATYNTGGCTCAG, 1492R: TASGGHTACCTTGTTASGACTT) that targeted the conserved 27F-1492R region. After library preparation and quality control, high-throughput sequencing was performed by Biomarker Technologies Co., Ltd. (Beijing, China). The sequences were clustered into operational taxonomic units (OTUs) at 97% similarity, and taxonomic classification was conducted using the RDP Classifier with the Silva database. Then, the microbial diversity was assessed using alpha diversity indices (Simpson, Shannon, Chao, ACE) for species richness and diversity within samples, and beta diversity for comparing the community structure and composition across samples. Statistical Analysis Statistical analyses were performed using SPSS version 13.0 (IBM, Armonk, NY, USA). For in vivo experiments in mice (n=25 per group), each mouse was treated as an independent biological observation. For in vitro examinations, the experiment was repeated five independent times. All data were presented in mean ± standard deviation (SD). The normality of the data was assessed using the Shapiro–Wilk test. Differences between groups were analyzed by two-way analysis of variance (ANOVA), followed by Tukey’s HSD post-hoc test for intergroup comparisons. A two-tailed p<0.05 was considered statistically significant. All graphs were generated using GraphPad Prism 10.0 (GraphPad Software Inc., Boston, MA, USA). The statistician was blinded to the study group allocations throughout the analysis. Results Probiotics in Combination with C16 Peptide and Ang-1 Synergistically Alleviated MS Severity in Mice In order to evaluate the therapeutic effects of probiotics in combination with C16+Ang-1 in the EAE mouse model of MS, the disease progression was monitored via clinical scores in the vehicle, probiotics, and C16+Ang-1+probiotics groups using the control group as the baseline. Symptoms in the vehicle group emerged at 12–14 days, pi, with scores exceeding 2, and peaking at 3–4 after three weeks, pi. In the C16+Ang-1+probiotics group, the clinical scores significantly decreased at the early (two weeks), peak (three weeks), and recovery (five weeks) stages, while in the probiotics group, the scores decreased at the peak (three weeks) and recovery (five weeks) stages (Figure 1A). Weight loss, which is the hallmark of EAE, was assessed in the groups. The control group gained weight, while all mice in the EAE-induced groups lost weight. Furthermore, the probiotics and C16+Ang-1+probiotics groups had slower weight loss at peak disease, and significant weight regain during recovery, achieving higher weights, when compared to the vehicle group, at the recovery stage (Figure 1B). These findings indicate that C16+Ang-1 enhanced the therapeutic effects of probiotics by reducing disease severity and weight loss. The vehicle group exhibited the lowest survival rate, followed by the probiotics group, while the C16+Ang-1+probiotics group had the highest survival rate (Figure 1C). Furthermore, EAE-induced mice showed significantly higher brain water content, when compared to normal mice (Figure 1D), suggesting brain edema. However, mice receiving probiotics combined with C16+Ang-1 showed significantly reduced brain water content, when compared to mice receiving probiotics alone (Figure 1D), indicating reduced disease severity. C16 and Ang-1 synergistically enhances the therapeutic effects of probiotics in EAE mice. (A) The C16+Ang-1 (C+A)+mixture of the probiotics group exhibits a stronger therapeutic effect against EAE, when compared to the other treatment groups. *p<0.05 vs the vehicle group; #p<0.05 vs the probiotics group; (B) Body weight was monitored daily starting from day 10 after EAE induction (initial weight = 18 g). The vehicle, probiotics, and C+A+probiotics groups all exhibited slowed weight loss, while the C+A+probiotics group promoted significant weight regain in recovery. *p<0.05 vs the control group; #p<0.05 vs the C+A+probiotics group; &p<0.05 vs the probiotics group. (C) The death rate of vehicle-treated EAE mice decreased after the probiotics treatment, and especially after the C+A+probiotics combination treatment. *p<0.05 vs the control group; #p < 0.05 vs the C+A+probiotics group; &p<0.05 vs the probiotics group. (D) The C+A+probiotics treatment resulted in the significant reduction of brain water content, when compared to the vehicle group and probiotics group. (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Effects of Probiotics, C16+Ang-1, and C16+Ang-1+probiotics on Gut Microbiota Composition and Diversity In order to evaluate the impact of probiotics alone or combined with C16+Ang-1 on gut microbiota, fecal samples were analyzed. A total of 1,003 OTUs were identified across the four groups (Figure 2A). Cluster analysis at the phylum and genus levels compared the effects of probiotics alone and the combination treatment (C16+Ang-1+probiotics) on intestinal flora composition (Figures 2B and C). The Shannon index revealed significantly higher gut microbiota diversity in the vehicle group, when compared to the control group. However, both the probiotics group and C16+Ang-1+probiotics group showed a significant reduction in Shannon index, when compared to the vehicle group, indicating decreased gut microbiota diversity with the combination treatment (C16+Ang-1+probiotics) (Figure 2D). The beta diversity analysis via principal coordinate analysis (PCoA) revealed the distinct clustering of samples. As shown in Figure 2E, the 95% confidence circles did not significantly overlap between the control (blue) and vehicle (orange) groups, indicating alternated intestinal flora composition in the vehicle group. In addition, the probiotics group (green) had more overlaps with the vehicle group, when compared with the C16+Ang-1+probiotics group (red), and there was a greater divergent from the control group (blue). The analysis of lactobacilli abundance revealed that Lactobacillus johnsonii (Figure 2F), Lactobacillus intestinalis (Figure 2G), and Limosilactobacillus reuteri (Figure 2H) were significantly lower in the vehicle group, when compared to the control group. Furthermore, the C16+Ang-1+probiotics group had a significantly increased abundance of these lactobacilli, when compared to both the vehicle and probiotics groups (Figures 2F–H). The C16+Ang-1 combined probiotics treatment altered the diversity and composition of the intestinal flora in mice. (A) Operational taxonomic unit (OTU) counts across the experimental groups. (B) Relative taxonomic abundance at the phylum level, as represented by stacked bar charts. (C) The bubble plot visualizes the composition of microbial species, with the bubble size corresponding to the relative abundance. (D) The alpha diversity assessed by the Shannon index; Student’s t-test was used for the statistical analysis (*p < 0.05). (E) The beta diversity was illustrated by principal coordinate analysis (PCoA), depicting the overall structural differences in bacterial communities. (F-H) The Linear discriminant analysis effect size (LEfSe) analysis of differentially expressed large intestinal flora in the experimental animals of each group. (F) Analysis of the differential expression of Lactobacillus johnsonii in the large intestines of experimental animals in each group. (G) Analysis of the differential expression of Lactobacillus intestinalis in the large intestines of experimental animals in each group. (H) Analysis of the differential expression of Limosilactobacillus reuteri in the large intestines of experimental animals in each group. p<0.05, n = 5. Enhanced Protective Effects of the Combined C16+Ang-1+probiotics Treatment on Intestinal Barrier Integrity The immunofluorescence staining images of ZO-1 in the colon, with the cell nuclei stained by Hoechst 33342, are illustrated in Figures 3A-D. The analysis revealed intact junctions in the colon of the normal group (Figure 3A), as indicated by the ZO-1 expression on the mucosal surface. Both the probiotics (Figure 3C) and C16+Ang-1+probiotics treatments (Figure 3D) significantly preserved the tight junction integrity, and reduced the mucosal permeability in EAE mice, while vehicle-treated mice presented with mucosal ulceration and decreased ZO-1 expression, indicating barrier disruption (Figure 3B). The probiotics alone and combination treatment in the C16+Ang-1+probiotics group restored the ZO-1 expression to varying degrees, with the latter exhibiting the strongest effects (Figure 3E). Protective effects of the C16 and Ang-1 (C+A), and C+A+probiotics treatments on intestinal barrier integrity in EAE mice. (A–D) Immunofluorescence staining images of ZO-1 (a specific tight junction marker, green) in the colon, with the cell nuclei stained by Hoechst 33342. (A) In normal mice, ZO-1 was obviously expressed on the surface of the intestinal mucosa. (B) In the vehicle treated group, there was a decrease in ZO-1 expression. (C) The ZO-1 expression increased in the probiotics group, when compared to the vehicle group. (D) Probiotics combined with C16+Ang-1 further increased the ZO-1 expression. (E) The quantification of ZO-1 expression (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. (F) Increased intestinal permeability, as indicated by the FITC-dextran absorption levels, was observed in the vehicle group. Permeability decreased in the probiotics group, and significantly decreased in the C+A+probiotics group. (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bar = 100 μm. The FITC-dextran absorption assays confirmed the increase in intestinal permeability in vehicle-treated mice, as indicated by the significantly higher serum FITC-dextran levels. These elevated levels were reduced with probiotics alone, and further decreased when combined with C16+Ang-1 (C16+Ang-1+probiotics) (Figure 3F). C16 and Ang-1 Enhanced the Effects of Probiotics in Reducing Vascular Leakage and Protecting BBB Permeability In order to evaluate the BBB protection, immunofluorescence staining was performed on the vascular endothelium for tight junction protein ZO-1 and endothelial receptor Tie-2, with nuclei counterstained using Hoechst 33342 (Figures 4A–D). ZO-1, a key tight junction protein (Figure 4E), and Tie-2, a vascular endothelial marker, were analyzed (Figures 4F). Compared to the normal group (Figure 4A), the immunofluorescence analysis revealed significant reductions in the expression of both proteins in the blood vessels of vehicle-treated EAE mice (Figure 4B). Notably, the combination of probiotics with C16+Ang-1 (Figure 4D) better preserved the endothelial integrity and tight junctions, when compared to probiotics alone (Figure 4C). Probiotics alone and in combination with C16+Ang-1 (C+A) preserves vascular integrity. (A–D) Representative immunofluorescence images of the vascular endothelium stained for tight junction protein ZO-1 (green) and endothelial receptor Tie-2 (red). Nuclei were counterstained with Hoechst 33342 (blue). (A) In normal mice, both ZO-1 and Tie-2 were obviously expressed in the blood vessel. (B) In the vehicle treated group, there was a decrease in both proteins. (C) The Probiotics treatment upregulated the Zo-1 and Tie-2 co-expression. (D) Probiotics combined with C16+Ang-1 further increased the expression. The quantification of the area positive for (E) ZO-1 and (F) Tie-2 showed that both treatments protected the endothelial cells and tight junctions, with the most pronounced effect observed in the C+A+probiotics group. Statistical significance: (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bar = 100 µm. Vascular leakage was evaluated by Evans blue analysis (Figures 5A–E). Compared to the normal group (Figure 5A), the BBB dysfunction phenomenon could be found in vehicle treated mice (Figure 5B). This might facilitate immune cell infiltration, and allow harmful substance to enter the CNS and promote disease progression. The treatment with probiotics alone (Figure 5C) and in combination with C16+Ang-1 (Figure 5D) mitigated these effects, with the C16+Ang-1+probiotics group presenting with a stronger inhibition of vascular leakage, when compared to the probiotics group (Figure 5E). Evaluation of blood-brain barrier (BBB) integrity in the different groups. Evans blue staining was used to assess the vascular permeability across the treatment groups. (A) In normal mice, there was no Evans blue leakage. (B) The representative images show the Evans blue leakage (pink-to-red signal under 405 nm excitation, indicated by arrows) in the vehicle group. (C) The probiotics treatment reduced the vascular permeability. (D) Probiotics combined with C16+Ang-1 further decreased the vascular leakage. (E) The quantification of dye extravasation confirmed that the C+A+probiotics combination was more effective in reducing leakage, when compared to probiotics alone. Statistical significance: (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bar = 100 μm. VEGF and MMP-9 are crucial in BBB disruption. If VEGF compromises barrier integrity and MMP-9 degrades the extracellular matrix, dysfunction would be exacerbated. The immunofluorescence staining of spinal cord tissues revealed significant increases in VEGF and MMP-9 expression in vehicle-treated EAE mice, when compared to the normal group (supplementary Figures 1A and B), while all treatments (supplementary Figures 1C and D), particularly the probiotics combined with C16+Ang-1 treatment (supplementary Figure 1D), reduced the expression (supplementary Figure 1E). C16 and Ang-1 Suppress Intestinal Inflammatory Cells and Protect Goblet Cells in the Colon Th17 cells (a subset of CD4+ T cells) are known for producing IL-17A, which is a pro-inflammatory cytokine linked to neuroinflammation.22 In mice with EAE, inflammation was evident through double immunofluorescence staining for IL-17A and CD4, in both the brain supplementary Figures 2A–D) and colon supplementary Figures 2E–H). In the normal group, only a few IL-17A+ cells were detected (supplementary Figures 2A and 2E). Vehicle-treated EAE mice presented with a significant increase in IL-17A+ cells (supplementary Figures 2B and 2F), which was reduced by treatments with probiotics (supplementary Figures 2C and 2G) or C16+Ang-1+probiotics (supplementary Figures 2D and 2H). Notably, the combination treatment in the C16+Ang-1+probiotics group led to a more effective reduction in IL-17A+ cells, when compared to the probiotics group (supplementary Figure 2Q). Furthermore, the immunofluorescence staining results evaluated by Statistical analysis (supplementary Figure 2R) revealed that the probiotics group supplementary Figure 2O), and specially the C16+Ang-1+probiotics group (supplementary Figure 2P), had a decreased expression of NK1.1 (a specific marker of natural killer cells), while this expression increased in the vehicle group in the colon (supplementary. Figure 2n), when compared to the normal group (supplementary Figure 2M). The AB-PAS staining highlighted the goblet cells in the colon. These are responsible for mucus production, which protects the intestinal mucosa. The goblet cell number reduced in the vehicle group (supplementary Figure 2J) vs the control group (supplementary Figure 2I), alongside the increase in inflammatory cell infiltration. In contrast, the mucosal morphology remained relatively normal in the probiotics (supplementary Figure 2K) and C16+Ang-1+probiotics groups (supplementary Figure 2L). C16 and Ang-1 Improved the Therapeutic Effects of Probiotics by Reducing CNS Inflammation and Modulating Microglial Polarization Some key cytokines in CNS inflammation and microglial polarization were examined in the different groups. CD68, which is a specific marker for macrophages and microglia, revealed that the vehicle treated group exhibited obviously increased CD68+ cells in the CNS, compared to normal mice supplementary Figures 3A and 3B). Both probiotics (supplementary Figures 3E and 3F) and C16+Ang-1+probiotics (supplementary Figures 3G and 3H) significantly reduced CNS inflammation in the probiotics and C16+Ang-1+probiotics groups, when compared to the vehicle group (supplementary Figures 3C and 3D), with more robust effects observed in the combination treatment (supplementary Figure 3I). The immunostaining for CD4 (Figures 6A–D in the spinal cord and Figures 6I–L in the colon), a specific marker for T lymphocytes, and CD19 (Figures 6E–H in the spinal cord and Figures 6M–P in the colon), a specific marker for B lymphocytes, revealed marked lymphocytes infiltration in the vehicle group, in both the spinal cord (Figures 6B–F) and colon (Figures 6J and N), when compared to normal mice (Figures 6A–M). The quantitative analysis revealed that both probiotics alone (Figures 6C–O) and in combination with C16+Ang-1 (Figures 6D–P) reduced the CD4 and CD19 positive cells, with the combination treatment demonstrating the most pronounced effects (Figures 6Q and R). Lymphocyte infiltration in the spinal cord and colon across the different experimental groups. Tissue sections were immunostained for T lymphocyte marker CD4 (red; (A–D) spinal cord, I-L colon) and B lymphocyte marker CD19 (green; (E–H) spinal cord, (M–P) colon). Pronounced inflammatory cell infiltration was observed in the vehicle group (B, F, J and N), when compared to the control group (A, E, I and M). Both the probiotic monotherapy (C, G, K and O) and C+A+probiotics combination treatment (D, H, L and P) alleviated this infiltration, with the combined treatment showing the most substantial reduction. The quantification of CD4+ and CD19+ cells confirmed that the C+A+probiotics treatment had the most significant effect both in the spinal cord (Q) and colon (R). Statistical significance: (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bar = 100 μm. The Nissl staining demonstrated the effects of different treatments on cellular infiltration in the spinal cord and brain cortex at three weeks, pi, and were consistent with the CD68 immunostaining results (supplementary Figure 4Q). This revealed noticeable neuron loss in the spinal cord and brain cortex of vehicle-treated EAE mice, when compared to controls, at the peak of EAE pathology (at five weeks, pi) supplementary Figure 4R). The neuronal loss in the motor cortex and spinal cord were significant in the vehicle group (supplementary Figures 4B–4N), when compared to the normal group (supplementary Figures 4A–4M), which was mitigated by probiotics (supplementary Figures 4C–4O) or C16+Ang-1+ probiotics (supplementary Figures 4D–4P), with the combination therapy providing the most significant protection. The serum levels of pro-inflammatory factors IL-1β (Figure 7A), IL-2 (Figure 7B), Il-6 (Figure 7C), and TNF-α (Figure 7D) were higher in vehicle-treated mice, when compared to controls, and these were mitigated by probiotics alone or combined with C16+Ang-1. Conversely, anti-inflammatory cytokine IL-10 was significantly suppressed in vehicle-treated mice, when compared to controls, and this was reversed by probiotics or C16+Ang-1+probiotics in the probiotics and C16+Ang-1+probiotics groups (Figure 7E). Notably, the combination treatment (C16+Ang-1+probiotics) exhibited stronger effects. In addition, COX-2 (Figures 8A–H) and NF-κB (Figures 8I–P), which are key transcription factors involved in inflammatory signaling pathways, were markedly upregulated in vehicle-treated mice (Figures 8B–N), when compared to controls (Figures 8A–8M). Both treatments with probiotics alone (Figures 8C–8O) and C16+Ang-1+probiotics downregulated (Figures 8D–P) COX-2 (Figure 8Q) and NF-κB (Figure 8R) in mice with EAE, with the combination treatment yielding a greater effect. Serum levels of key cytokines in mice in the different experimental groups. (A) IL-1β, (B) IL-2, (C) IL-6, (D) TNF-α, and (E) IL-10 were examined using enzyme-linked immunosorbent assay. The probiotics and C+A+probiotics groups had decreased levels of IL-1β, IL-6, IL-2 and TNF-α, and increased levels of IL-10 in serum. (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Expression levels of important transcription factors in inflammatory pathways (A–P) The COX-2 (green) and NF-κB (red) expression significantly increased in vehicle-treated EAE mice (COX-2, (B and F); NF-κB, (J and N)), when compared to the control group (COX-2, (A and E); NF-κB, (I and M)), while the probiotics alone (COX-2, (C and G); NF-κB, (K and O) and in combination with C+A (COX-2, D and H; NF-κB, L and (P) treatments reduced the expression levels of these pro-inflammatory factors. The quantification of COX-2-labeled (Q) and NF-κB-labeled (R) cells indicated that the probiotics treatment had a lesser effect, when compared to the C+A+probiotics group. (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bar = 100 μm. In order to further investigate the mechanisms for the effects of different treatments, the microglial polarization in mice with EAE treated with probiotics alone and combined with C16+Ang-1 was analyzed (Figures 9A–E). The immunofluorescence staining images indicated that vehicle-treated EAE mice decreased CD206 and increased CD86, when compared to the normal group (Figures 9A and B), while probiotics alone and the combination with C16+Ang-1 treatments (Figures 9C and D) significantly promoted M2 polarization by upregulating CD206 and downregulating CD86, reversing the effects in the vehicle group (Figures 9E). Modulation of microglial polarization in the different treatment groups. (A–D) Representative immunofluorescence images. (A) Normal mice; (B) In the vehicle treated group, there was an increase in CD86 (green) expression; (C) The CD206 (red) expression increased in the probiotics group, when compared to the vehicle group. (D) Probiotics combined with C16+Ang-1 further increased the CD206 expression. (E) Quantitative analysis of microglial markers CD86 (inflammatory) and CD206 (protective). The C+A+probiotics group exhibited a significant shift in microglial phenotype, as marked by a higher ratio of CD206+ cells and the suppression of CD86+ expression, when compared to the other treatment groups. Statistical significance: (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bars = 100 µm. C16 and Ang-1 Synergize with Probiotics to Protect Against Demyelination and Axonal Damage in the Mouse Model of MS The effects of probiotics alone and the combination with C16 and Ang-1 on demyelination and axonal damage, which are hallmark features of MS and EAE, were examined. The immunohistochemical staining for NF-H (a specific marker for axons and neuronal cell bodies) and MBP (a myelin-specific marker) revealed the severe demyelination in EAE mice (Figures 10C and D), when compared to normal mice (Figures 10A and B). This was alleviated by probiotics alone (Figures 10E and F) and the combination with C16+Ang-1 (Figures 10G and H), with the combination treatment exhibiting superior myelin preservation and axonal integrity (Figures 10I and J). The Eriochrome Cyanine R staining for demyelination (supplementary Figure 5) and Bielschowsky staining for axonal integrity (Suppl. Figure 6) revealed the intact myelin (supplementary Figures 5A and 5B) and axons (supplementary Figures 6A and 5B) in the normal group, and the demyelination (supplementary Figure 5C and 5D) and axonal loss (supplementary Figures 6C and 6D) in the vehicle group. The probiotics (Supplementary. Figures 5E and 5F and Supplementary. Figures 6E and 6F) and C16+Ang-1+probiotics groups (supplementary Figures 5G and 5H and supplementary Figures 6G and 6H) reduced these phenomena, with a stronger protective effect in the latter group (supplementary Figure 5I and Supplementary. Figure 6I). Neuroprotective effects on the amelioration of demyelination and axonal injury in various treatment groups. (A–D) Double staining for myelin basic protein (MBP, green) and neurofilament-H (NF-H, red) in the control group ((A), brain cortex; (B), spinal cord), vehicle group ((C), brain cortex; (D), spinal cord), probiotics alone group ((E), brain cortex; (F), spinal cord), and C+A+probiotics group ((G), brain cortex; (H), spinal cord), along with the corresponding quantifications analyses of axon marker NF-H (I) and myelin marker MBP ((J)). The C+A+probiotics regimen induced a more robust increase in both the MBP and NF-H expression, signifying the greater amelioration of demyelination and axonal injury, when compared to probiotics alone. Statistical significance: (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bars = 100 µm. The electron microscopy images of neurons and analyses are shown in Figures 11A–M. Normal neurons with myelinated axons exhibited dark ring-shaped myelin sheaths surrounding the axons (Figure 11E), but there was no edema surrounding the blood vessels (Figure 11I). The TEM revealed perivascular edema and enlarged perivascular spaces in the vehicle group (Figure 11J), and these were markedly improved by probiotics, particularly the probiotics combined with C16+Ang-1 (Figures 11K and L). Furthermore, notable myelin sheath alterations were identified in the vehicle group, including loosening, fusion, splitting, and vacuole formation (Figure 11F). In contrast, both treatments with probiotics and C16+Ang-1+probiotics exhibited reduced myelin pathology. Compared to vehicle-treated mice (Figures 11G and H), the G-ratio analysis (axon diameter/fiber diameter) indicated enhanced myelin integrity, especially in the C16+Ang-1+probiotics group (Figure 11M). These results suggest that the combination of C16-Ang-1 with probiotics produce a synergistic effect to mitigate EAE-induced demyelination, axonal loss, and edema. Electron microscopy images. Control tissues presented with neurons with non-condensed chromatin (A), intact myelinated axons (E), and no evidence of vascular edema (I). In the EAE model, the neurons presented with shrunken nuclei with fragmented chromatin (B), while axons exhibited significant demyelination and shrinkage (F). The perivascular regions presented with severe edema and enlarged spaces (J). The probiotics treatment resulted in the marked preservation of nuclear (C), axonal, and myelin (G) morphology, with a reduction in perivascular edema (K). In the C+A+probiotics group, the nuclei morphology (D), myelin and axons (H), and blood vessels (L) were more closely approximated, when compared to the normal group. Scale bar = 2 μm. (M) The G-ratio of each group was measured by ImageJ. (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. C16 and Ang-1 Synergize with Probiotics to Reduce Neuronal Death in the Mouse Model of MS In order to assess the neuroprotection, the neuronal apoptosis in mice with EAE was examined. The TEM results revealed that the nuclei of normal neurons presented with uncondensed chromatin (Figure 11A), while vehicle-treated EAE mice presented with apoptotic features, such as nuclear condensation and fragmentation (Figure 11B). The treatment with probiotics or C16+Ang-1+ probiotics preserved the nuclear integrity, and reduced apoptosis (Figures 11C and D). The immunohistochemistry results for cleaved caspase-3 are presented in Figures 12A–I. At three weeks, pi, EAE mice presented with an increased expression of cleaved caspase-3 in pyramidal motor neurons (precentral gyrus) (Figure 12C) and large multipolar motor neurons (spinal cord anterior horn) (Figure 12D), when compared to the normal group (Figures 12A and B). In contrast, the cleaved caspase-3 levels significantly decreased in the probiotics (Figures 12E and F) and C16+Ang-1+probiotics (Figures 12G and H) groups. The quantitative analysis of caspase-3 positive cells (Figures 12I) aligned with the TUNEL results at the same time point supplementary Figure 7I), which revealed the increase in positive cells in the vehicle group (supplementary Figures 7C and 7D), when compared to the normal group (supplementary Figures 7A and 7B). Notably, the combination of probiotics with C16+Ang-1 (supplementary Figures 7G and 7H) exhibited a stronger reduction in neuronal apoptosis, when compared to probiotics alone (supplementary Figures 7E and 7F). Inhibitory effects of probiotics alone and in combination with C+A on EAE-induced neuron apoptosis. (A–H) The immunohistochemistry for cleaved caspase-3, with a key role in the apoptotic pathway for programmed cell death in the control group ((A), brain cortex; (B), spinal cord), vehicle group ((C), brain cortex; (D), spinal cord), probiotics alone group ((E), brain cortex; (F), spinal cord), and C+A+probiotics group ((G), brain cortex; (H), spinal cord), with the corresponding quantifications analysis of cleaved caspase-3 ((I)). (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bar = 100 μm. The FG retrograde tracing further confirmed the neuronal loss in the primary motor cortex and anterior horn of the cervical spinal cord in EAE mice (Figures 13C and D), when compared to controls (Figures 13A and B), with this pathology alleviated by probiotics alone and the combination treatment (Figures 13I). Collectively, these findings indicate that the probiotics (Figures 13E and F) and C16+Ang-1+probiotics (Figures 13G and H) treatments can effectively preserve neurons, and reduce cell death, with the strongest neuroprotection observed in the C16+Ang-1+probiotics group. Effects of probiotics alone and in combination with C16+Ang-1 on Fluorogold-labeled neurons in the motor cortex and spinal cord. (A–I) Fluorogold-labeled neurons in the motor cortex and spinal cord in the control group ((A), brain cortex; (B), spinal cord), vehicle group ((C), brain cortex; (D), spinal cord), probiotics alone group ((E), brain cortex; (F), spinal cord), and C+A+probiotics group ((G), brain cortex; (H), spinal cord). The corresponding quantifications analysis of the Fluorogold-labeled neurons (I) revealed that the treatment with probiotics alone and in combination with C16+Ang-1 significantly alleviated the decrease in Fluorogold-labeled neurons in the motor cortex and spinal cord, when compared to vehicle-treated EAE mice. C+A+probiotics obtained more intact neurons, when compared to the other two groups. (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bar = 100 μm. Probiotics Alone and C16+Ang-1+probiotics Activate Akt and Suppress Astrocyte Activation The effects of treatments with probiotics and C16+Ang-1+probiotics on Akt expression are presented in Supplemental Figures 8A–I. Vehicle-treated mice presented with lower Akt expression in the motor cortex (supplementary Figure 8B) and spinal cord (supplementary Figure 8F), when compared to the normal group (Supplementary. Figures 8A and E). The treatment with probiotics (supplementary Figures 8C and 8G) or C16+Ang-1+probiotics (supplementary Figures 8D and 8H) significantly increased the Akt expression in the motor cortex and spinal cord of EAE mice, when compared to vehicle-treated mice (supplementary Figure 8I). GFAP, which is a specific biomarker for activated astrocytes strongly associated with reactive astrogliosis, glia scar formation, and adverse conditions for neuronal axons regeneration, is also a hallmark of CNS inflammation. Vehicle-treated EAE mice (Figures 14C and D) presented with increased GFAP+ astrocyte counts in both the cortex and spinal cord, when compared to the normal group (Figures 14A and B). In contrast, the probiotics (Figures 14E and F) and C16+Ang-1+probiotics (Figures 14G and H) treatments significantly reduced astrocyte reactivity, and the combination treatment exhibited the greatest effects (Figure 14I). Activated astrocytes in the central nervous system (CNS) stained with GFAP. (A–H) The expression of astrocytes marker GFAP in the control group ((A), brain cortex; (B), spinal cord), vehicle group ((C), brain cortex; (D), spinal cord), probiotics alone group ((E), brain cortex; (F), spinal cord), and C+A+probiotics group ((G), brain cortex; (H), spinal cord). (I) The corresponding quantifications analysis of GFAP revealed that the treatment with probiotics alone and in combination with C+A inhibited astrocyte proliferation and glial scar formation in EAE mice, with better effectiveness in the combination treatment. (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bar = 100 μm. Effects of Probiotics and C16+Ang-1 on Neurotransmitter Expression in the Colon The effects of probiotics and C16+Ang-1 on neurotransmitter expression in the colon were investigated (Figures 15A–T). The analysis of neurotransmitter levels in the colon revealed that when compared to the normal group (Figures 15A–M), there was a decrease in expression of 5-serotonin (5-HT, Figure 15B), gamma-aminobutyric acid (GABA, Figure 15F), and choline acetyltransferase (CHAT, Figure 15N) in vehicle-treated EAE mice, while the glutamine expression increased (Figure 15J). In contrast, the treatment with probiotics (Figures 15C–O), especially probiotics combined with C16+Ang-1 (Figures 15D–P), significantly elevated the 5-HT (Figure 15Q), GABA (Figure 15R), and CHAT (Figure 15T) expression, but reduced the glutamine expression in the colon (Figure 15S). Effects of probiotics and C+A+probiotics on the expression levels of neurotransmitters 5-serotonin (5-HT), gamma-aminobutyric acid (GABA), glutamine, and choline acetyltransferase (CHAT) in the gut. Immunofluorescence staining of 5-HT (red, (A), normal group; (B), vehicle group; (C), probiotics alone group; (D), C+A+probiotics group), GABA (red, (E), normal group; (F), vehicle group; (G), probiotics alone group; (H), C+A+probiotics group), glutamine (green, (I), normal group; (J), vehicle group; (K), probiotics alone group; (L), C+A+probiotics group), and CHAT (green, (M), normal group; (N), vehicle group, (O), probiotics alone group; (P), C+A+probiotics group), with the nuclei stained with Hoechst 33342. The quantitative analysis indicated an increase in 5-HT (Q), GABA (R) and CHAT (S), and revealed a decrease in glutamine (T) in the colon in the probiotics and C+A+probiotics groups. (a) p<0.05 vs the control group; (b) p<0.05 vs the vehicle group; (c) p<0.05 vs the probiotics group. Scale bar = 100 μm. Discussion The present in vivo study was the first to determine whether combining probiotics with C16-Ang-1 has a synergistic effect on alleviating MS in mice, and explore the underlying mechanisms. The key findings were, as follows: (1) The combination of probiotics and C16+Ang-1 demonstrated significant synergistic effects, when compared to probiotics alone. (2) The combined treatment enhanced the therapeutic effects by more effectively reducing inflammatory severity in the CNS and colon, improving the local microenvironment, protecting the gut-blood barrier, and preserving BBB integrity. Collectively, these improvements resulted in the greater reduction of functional disability in the mouse model of MS. (3) The mechanistic analysis revealed that these beneficial effects involved the modulation of the brain-gut axis, maintenance of gut microbiota homeostasis, and regulation of key inflammatory signaling pathways. It may merit attention in this study that C16-Ang-1 functions by targeting the BBB and CNS microvasculature, in which the C16 peptide blocks integrin αvβ3-mediated leukocyte adhesion and transmigration,18,23 while Ang-1 activates the Tie-2 receptor to stabilize endothelial junctions and reduce vascular permeability.24 Thus, C16-Ang-1 physically limits the entry of pathogenic immune cells and inflammatory mediators into the CNS. Simultaneously, probiotics diminish the upstream immunological triggers that activate autoreactive T cells, and prime these for CNS invasion by restoring gut microbiota homeostasis, reducing intestinal permeability, and suppressing systemic low-grade endotoxemia (eg LPS translocation).25 Therefore, the novelty of the present study lies in the synergistic integration of these two interventions. This dual-target approach may constitute a new therapeutic paradigm distinct from all existing monotherapeutic models. The gastrointestinal (GI) tract, which is exposed to food antigens and the gut microbiome, interacts with the CNS.26 This is protected by three barriers: a thick mucus layer (produced by goblet cells), a semipermeable enterocyte monolayer, and a gut-vascular barrier (GVB) that consists of endothelial cells, pericytes, and enteric glial cells.27 Furthermore, the gut contains numerous immune cells in response to stimuli. Intestinal inflammation can release IL-1β, IL-6, IFN-γ, and TNF-α, and these pro-inflammatory cytokines damage these barriers, increasing intestinal permeability, and allowing harmful substances to enter the bloodstream. It has been found that the gut-brain axis regulates inflammatory responses and immune homeostasis, since microbes or its products can enter circulation, disrupt the BBB, and affect CNS function.27 Compromised BBB integrity permit toxins and pathogens to reach the CNS, triggering neuroinflammation. In the early stages of MS, this results in immune cell infiltration into the CNS, and subsequent grey matter atrophy.28 Furthermore, intestinal immune cells, such as IgA+ plasma cells, can migrate to the CNS and spinal cord, and suppress IL-10-dependent neuroinflammation in an IL-10-dependent manner. In the present study, it was initially demonstrated that the ZO-1 expression, which indicates the intact junctions between the epithelial cells of blood vessels and intestinal mucosa, was lost in vehicle-treated EAE mice. Furthermore, there was increased leakage from the blood vessel and elevated water content in the CNS, suggesting damage to both the GVB and BBB. Consistent with these findings, the ELISA assays revealed elevated proinflammatory cytokines, such as IL-2, IL-6, IL-1β and TNF-α, following EAE induction, indicating a systemic-humoral pathway that disrupts the CNS microenvironment. Notably, the probiotics treatment and C16+Ang-1 combined with probiotics treatment suppressed these proinflammatory cytokines, but increased the IL-10 anti-inflammatory cytokine in serum. Although the treatment with probiotics alone had a weaker effect, the synergistic application of C16+Ang-1 significantly enhanced the protection effects on junction integrity and anti-inflammatory response. Beyond the humoral immune pathway, intestinal T and NK cells can directly promote CNS neuroinflammation. Its migration to the CNS is implicated in the pathogeneses of neurodegenerative and neurological diseases. In MS, gut microbiota promotes intestinal myelin-reactive T cells, and pro-inflammatory Th1 and Th17 cells migrate to the CNS to promote inflammation, contributing to the disease, while regulatory T-cells (Tregs) suppresses this process.29 Dysbiosis and a “leaky” gut exacerbate this inflammatory and immune response, making it a potential therapeutic target. Specifically, pro-inflammatory Th1 and Th17 cells mediate inflammatory damage, while Tregs suppress post-ischemic inflammation via anti-inflammatory cytokines, such as IL-10.30 Intestinal Th17 cells, which secrete IL-17A, are critical for homeostasis, and play key roles in driving extra-intestinal autoimmune diseases, including MS.28 Accordingly, inhibiting gut Th17 cell infiltration and NK cell activation can suppress the progression of MS.31 In the present study, Th17 cells labeled by the IL-17A antibody increased in both the CNS and colon of mice with EAE. Similarly, the expression of CD4 (a specific marker of T lymphocytes) and CD19 (a specific marker of B lymphocytes), as well as NK1.1 (a specific marker of NK cells), all significantly decreased with the probiotics treatment, especially when combined with C16+Ang-1. Notably, the combination treatment of C16+Ang-1 with probiotics led to more effective results, when compared to probiotics alone. These enhanced effects may be attributed to the additional functions of the C16+Ang-1 compound in targeting the transmigration of inflammatory cells, maintaining blood vessel integrity, and improving the inflammatory environment, while the probiotics mainly acted on modulating the gut-brain axis, and maintaining the balance of the gut microbiome. The enteric nervous system (ENS), which is located in the walls of the GI tract, directly interfaces with the intercellular space to facilitate nutrient absorption. Its ganglia are surrounded by glial cells with a basement membrane, and contain capillaries with a continuous endothelium, forming a “blood-enteric nerve plexus barrier” similar to the BBB. ENS neurons connect the GI tract to the CNS, transmitting inflammatory signals, and triggering the CNS response to maintain gut-brain axis homeostasis.32 Thus, the gut microbiota influences both the immune function and development of diseases in the gut and CNS. An imbalance in glutamate and GABA, which is characterized by excess glutamate and reduced GABA, would lead to neuro-excitation,33 exacerbating symptoms in conditions, such as MS, and damages to the myelin sheath surrounding neurons.34 Probiotics may alleviate this imbalance by modulating the GABA, glutamate, and dopamine pathways, reducing neuroinflammation, and restoring gut flora balance.34,35 Acetylcholine (ACh), which is synthesized by choline acetyltransferase (ChAT) and broken down by acetylcholinesterase (AChE), is reduced in inflammatory bowel diseases (IBDs, the immune-mediated destruction of the intestine). ACh administration ameliorates colitis by directly expanding monocytic myeloid-derived suppressor cells (M-MDSCs), and promoting IL-10 secretion via the nAChR/ERK pathway.36 The decrease in ChAT is linked to enteric inflammation, and ChAT+ lymphocytes help regulate inflammation and anti-microbial defense.37 Furthermore, 5-HT is another key messenger in the intestinal epithelium, and is involved in intestinal inflammation.38 Modulating the 5-HT signaling can help treat irritable bowel syndrome, and the stimulation of 5-HT4 receptors may repair ENS neural circuits.39 Furthermore, the increase in 5-HT may reshape the gut microbiota, and enhance neuroprotection.40 Since the balance of the gut microbiota is closely related to the changes in neurotransmitter levels, supplementing with probiotics can upregulate the expression of 5-HT, GABA and ChAT, and decrease the glutamine expression in the colon. Furthermore, since the C16+Ang-1 compound itself possesses the ability to increase probiotics, such as Lactobacillus johnsonii, in the gut, this may have synergistic effects when combined with probiotics. Previous studies have revealed that short-chain fatty-acid-producing microbes (ie Eubacterium hallii, Blautia, and Butyricoccaceae) are beneficial for improving disability.41 These microbes and metabolites may serve as targets for treating MS, and modifying the gut-brain axis through specific probiotics or dietary interventions, representing a complementary approach alongside conventional immune therapies for MS.42 Recent studies have revealed the beneficial effects of Lactiplantibacillus plantarum on motor and cognitive symptoms, indicating that probiotics may enhance anti-inflammatory mechanisms, and mitigate cellular oxidative processes in neurodegenerative diseases.42 The present findings indicated the significant improvements in the inflammatory environment of the CNS in both treatment groups. In addition, the extracellular edema that resulted from the increase in vascular permeability was markedly reduced. The anti-inflammatory and antioxidant effects of both treatments protected the myelin sheaths and neuronal axons, preserving cell membrane integrity, while reducing apoptosis and necrosis. This enhancement of the inflammatory environment also inhibited reactive astrocyte proliferation and decreased glial scar formation, which can hinder axonal regeneration. As a result, the treatment group had less neuron loss after the acute phase, leading to noticeable improvements in neurological function among the treated mice. The PI3K/Akt pathway is critical for neuronal survival and CNS functions, including autophagy and synaptic plasticity. A previous research revealed that artemisinins may protect against neurodegeneration by modulating the PI3k/Akt pathway, thereby reducing oxidative stress, apoptosis, and neuroinflammation.43 Similarly, the mixture of Lactobacillaceae has been shown to reduce fasting blood glucose (FBG) inflammatory markers by enhancing PI3K/Akt signaling and SCFA production.44 Specific probiotics and its metabolites also exhibit anti-inflammatory effects. For instance, Lactobacillus plantarum-derived extracellular vesicles can promote the polarization of anti-inflammatory M2 macrophages,45 and ursodeoxycholic acid from Lactobacillus acidophilus can improve ulcerative colitis by boosting Treg cells to increase the secretion of anti-inflammatory cytokines, as well as inhibiting M1 macrophages to decrease pro-inflammatory cytokines.46 Another previous research indicated that quercetin can decrease M1 microglia/macrophages, while increasing M2 microglia/macrophages through the PI3K/Akt/NF-κB signaling pathway.47 Similarly, the present findings suggest that modulating microglial polarization and promoting the PI3K/Akt signaling pathway may be integral to the metabolism of probiotic treatments. However, the beneficent effects were limited when probiotics were used alone, possibly because the C16+Ang-1 compound also targets the same pathway to suppress the M1 phenotype and promote the M2 phenotype of microglia.48 Just as tight junction in the blood vessel requires integrins to maintain barrier function, intestinal epithelial cells also rely on integrins to preserve its barrier integrity.48 The C16 peptide may act as an agonist of alpha V, potentially decreasing the permeability of the intestinal mucous. Furthermore, Ang-1 can protect blood vessels and maintain BBB integrity by activating Ang-Tie-2 signaling pathways, thereby simultaneously protecting the GVB and BBB.49 The host microbiota plays a critical role in immune response, pathogen defense, and maintaining proper homeostasis.50,51 In a previous study conducted by the investigators, C16 peptide combined with Ang-1 improved the inflammatory cell infiltration, BBB leakage, and neuroblast damage in the EAE model.9 In the present study, the utilized probiotics comprised mainly of Lactobacillus. Therefore, the results further confirmed the beneficent effects of supplementing with Lactobacillus on the recovery of EAE mice, and verified that C16+Ang-1+probiotics can yield even better results. The 16S rRNA sequencing is a widely used method for exploring the composition of the intestinal flora, describing the microecological structure and diversity, and monitoring probiotics and opportunistic bacteria.52 In the present study, 16S rRNA sequencing was applied to compare the intestinal microflora in the control, vehicle, probiotic, and C16+Ang-1+probiotic groups. Feces were collected from the experimental animals at 14–16 days, pi, and the microorganisms were classified, identified, and characterized. The sequences were divided into OTUs based on similarity, yielding 1,039 OTUs from four groups. In order to compare the effects of probiotics alone and in combination with C16+Ang-1 on the intestinal flora composition, cluster analysis was conducted at both the phylum and genus level. At the phylum level, microorganisms with high abundance mainly included Firmicutes, Bacteroidota, Proteobacteria, Desulfobacterota, Verrucomicrobiota, Campylobacterota, Actinobacteriota, Verrucomicrobiota, and Cyanobacteria. Compared to the normal group, Firmicutes and Verrucomicrobiota were significantly reduced in the vehicle group, while the abundance of Bacteroidota and Proteobacteria significantly increased. At the genus level, the abundance of Lactobacillus and the probiotic Faecalibaculum,53 which is known for anti-inflammatory effects, was significantly lower in the vehicle group, when compared to the control group. Compared to the vehicle group, the abundance of Faecalibaculum in EAE mice supplemented with probiotics alone significantly increased. Furthermore, the abundance of Dubosiella significantly increased in EAE mice after the C16+Ang-1 and probiotics treatment. Dubosiella54 is a symbiotic bacterium that helps rebalance the Treg/Th17 response and ameliorate mucosal barrier damage by producing short-chain fatty acids, such as propionic acid and L-lysine. In the present study, the ZO-1 immunofluorescence and FITC-Dextran results confirmed that the C16+Ang-1+probiotics treatment reduced intestinal permeability more effectively in EAE mice. These results indicate that probiotics alone can reshape the intestinal flora of EAE mice, while the combination treatment with C16+Ang-1+probiotics had a more significant therapeutic effect. The richness and diversity of the gut microbiota were evaluated using alpha diversity.55 Compared to the control group, the Shannon index was significantly greater in the vehicle group, indicating increased diversity. In contrast, the Shannon index in the probiotics group and C16+Ang-1+probiotics group was significantly reduced, when compared to the vehicle group, suggesting that the drug treatment and probiotics supplementation decreased the alpha diversity of the gut microbiota in EAE mice. Beta diversity analysis was conducted to compare the similarity among different samples, in terms of species diversity.51 In the PCoA diagram, the samples were clustered based on composition, with similar samples closer together. The 95% confidence circle between the control group and vehicle group did not significantly overlap, indicating a change in intestinal flora composition in the vehicle group. In addition, compared to the C16+Ang-1+probiotic group, the probiotic group had more overlaps with the vehicle group, and was further from the control group. These results indicate that the intestinal flora of EAE mice was disordered, with significant decreases in probiotic species, such as Lactobacillus and Faecalibaculum. Probiotics, which are mainly derived from Lactobacillus, partially alleviated the gut pressure in EAE mice, reduced the permeability of the intestinal barrier, and increased the number of probiotics. However, since it only contains a part of specific probiotics, its effects were limited. Furthermore, since the C16+Ang-1 compound improved the intestinal probiotics by adjusting various species of probiotics, such as Lactobacillus and Faecalibaculum, when supplemented with an appropriate dose of oral probiotics mainly composed by Lactobacillus, this better reshaped the intestinal microecology, and balanced the intestinal flora. The present study further compared intestinal microbial communities among experimental animals in the control, vehicle, probiotics, and C16+Ang-1+probiotics groups. The results revealed that the abundance of lactobacilli, such as Lactobacillus johnsonii, Lactobacillus intestinalis, and Limosilactobacillus reuteri, was significantly lower in the vehicle group, when compared to the control group. The supplementation with Lactobacillus johnsonii, which is a probiotic, can improve the damage of colonic goblet cells, reduce the colonic pathological damage, increase the ZO-1 protein expression, and enhance the stability of the intestinal barrier.56 The combination of Lactobacillus intestinalis and mesalazine synergistically alleviates colitis in mice,57 and its increased abundance is closely associated with improved intestinal barrier permeability.58 Limosilactobacillus reuteri enhances intestinal health, immune regulation, and antibacterial activity. Jang et al59 reported that Limosilactobacillus reuteri can inhibit intestinal inflammation by regulating LPS infiltration into the brain, and increasing the expression of brain-derived neurotrophic factor (BDNF), thereby alleviating anxiety and depression-like symptoms in mice. The present study revealed that the probiotics treatment increased the abundance of Lactobacillus johnsonii and Lactobacillus intestinalis in EAE mice. The further increase in lactobacilli abundance in the C16+Ang-1+probiotics group improved the efficiency, when compared to the vehicle and probiotics groups. Based on the present findings and the findings of others discoursed above, the investigators propose the following mechanisms by which the C16-Ang-1+probiotics alleviates the symptoms of MS in the mouse model: (1) Oral Lactobacillus plantarum acts to restore gut microbial homeostasis, thereby reducing gut permeability, and limiting LPS translocation into the systemic circulation. The resulting reduction in circulating endotoxins attenuates peripheral innate immune activation, and lowers systemic pro-inflammatory cytokines, decreasing the encephalitogenic potential of myelin-reactive T cells; (2) Concurrently, C16-Ang-1 can stabilize the BBB via two complementary mechanisms: C16 peptide blocks integrin αvβ3-mediated leukocyte adhesion and transmigration, while Ang-1 activates Tie-2 to tighten endothelial junctions and reduce vascular permeability; (3) The synergistic effect of the reduced peripheral inflammatory burden and reinforced vascular barrier decreases leukocyte infiltration into the CNS, attenuating local inflammation, demyelination, and neuronal injury. The resulting preservation of myelin and neuronal structures ultimately translates into functional motor recovery. Furthermore, the present study suggests that the combination of C16-Ang-1 and probiotics may have broader applicability beyond MS/ EAE to other conditions characterized by gut dysbiosis and BBB disruption. These conditions include neuromyelitis optica spectrum disorder, post-infectious neuroinflammatory syndromes, sepsis-associated encephalopathy, neurodegenerative disorders with inflammatory components (such as Parkinson’s and Alzheimer’s diseases), and graft-versus-host disease with neurological involvement. The investigators indeed previously tested the effects of C16-Ang-1 in various experimental models, including the amyotrophic lateral sclerosis/Parkinsonism dementia complex,60 neuromyelitis optica,61 Parkinson’s disease,14,62 Alzheimer’s disease,63 and 3-nitropropionic acid-induced dystonia.64 All of these are neurodegenerative diseases associated with inflammation within the CNS. Therefore, future studies are warranted to explore the broader applications of the C16-Ang-1 and probiotics combination for these diseases. The present study may have several limitations. First, the peptide/protein-based C16+Ang-1 compound face challenges in long-term delivery. Intramuscular injection has limited vascular access, while prolonged intravenous administration can induce phlebitis due to the irritant properties of the acidic solvent. In order to address this issue, a DSPE-PEG2000 liposome system, which can form liposomes with a particle size of 30–40 nm, would be employed, allowing for co-solubility and self-assembly in aqueous solutions, thereby effectively enhancing the transport of the C16+Ang-1 compound across the BBB.65 Most importantly, these novel nano-carriers with N-formylmethionyl-leucyl-phenylalanine-modified liposomes would not induce phlebitis upon application. The safety of long-term use has not yet been clinically tested, and would require further toxicological studies in the future. Second, due to the potential immunogenicity of peptide- and protein-based therapies, the present investigational treatments must be assessed for safety with long-term or repeated use, and regulatory approval requires extensive preclinical toxicology and safety studies. Third, although the EAE model captured the key aspects of MS pathology, it does not fully mirror the heterogeneity of the human disease. Future clinical trials would need to account for variability in immune response, disease stage, and comorbidities. Conclusions In conclusion, the present study in a mouse model of MS demonstrates that combining probiotics with C16-Ang-1 produces a synergistic therapeutic effect. This effect is likely attributable to different yet complementary mechanisms of action, whereby the treatments work together to modulate the gut-brain axis and systemic immunity, promote BBB integrity, and reduce CNS inflammation. Thus, this dual-target approach may represent a new therapeutic strategy. These promising findings warrant further investigation to explore its potential clinical benefits, and translate this combination treatment into clinical trials, ultimately improving the care for patients with MS.